Most antidepressants are metabolized through the cytochrome P (CYP) 450 pathway; therefore, most drug metabolism genes on pharmacogenetic testing panels are related to CYP450 oxidase enzyme subunits.

Pharmacogenetic testing, which is used to classify how patients with major depressive disorder (MDD) metabolize medications, reduces adverse drug-gene interactions, new research shows. In a randomized ...

"The most striking finding was the realization that the test wasn't useful most of the time. This is seen in the control condition in which about 20% of patients were started on a medication with a ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Testing for genetic variants may allow clinicians to predict how patients with major depressive disorder metabolize antidepressants. Each month, The Clinical Advisor makes one new clinical feature ...